Testing the Combination of DS-8201a and Olaparib in HER2-Expressing Cancers With Expansion in Patients With Platinum Resistant Ovarian Cancer

חו"ל (דורש נסיעה)מגייס משתתפיםPHASE1

מצבים רפואיים

Metastatic Malignant Solid Neoplasm · Platinum-Resistant Ovarian High Grade Serous Adenocarcinoma · Unresectable Malignant Solid Neoplasm

הסיכום נכתב על־ידי מודל שפה והוא ניסיוני. המידע עלול להיות חלקי או שגוי ואינו תחליף לייעוץ רפואי.

מיקומים

Mayo Clinic Hospital in Arizona, Phoenix, Arizona, United States
Mayo Clinic in Florida, Jacksonville, Florida, United States
Contact: Study coordinator (Site Public Contact) · 855-776-0015
Contact: Principal Investigator (Andrea E. Wahner Hendrickson)
Emory University Hospital Midtown, Atlanta, Georgia, United States
Contact: Study coordinator (Site Public Contact) · 888-946-7447
Contact: Principal Investigator (Kristen Starbuck)
Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States
Contact: Study coordinator (Site Public Contact) · 404-778-1868
Contact: Principal Investigator (Kristen Starbuck)
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Contact: Study coordinator (Site Public Contact) · 877-442-3324
Contact: Principal Investigator (Elizabeth K. Lee)
Mayo Clinic in Rochester, Rochester, Minnesota, United States
Contact: Study coordinator (Site Public Contact) · 855-776-0015
Contact: Principal Investigator (Andrea E. Wahner Hendrickson)
University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania, United States
Contact: Study coordinator (Site Public Contact) · 412-647-8073
Contact: Principal Investigator (Sarah E. Taylor)

מובילי המחקר